Clinical Research Directory
Browse clinical research sites, groups, and studies.
The Cardiovascular Effect of GLP-1 Agonist, SGLT2 Inhibitor and Their Combination
Sponsor: University of Athens
Summary
A. Four groups of patients with type 2 diabetes mellitus with high or very high cardiovascular risk or heart failure with preserved ejection fraction (HFpEF) will be studied before and at 6 and 12 months of treatment: * 60 patients treated with a combination of GLP1 analogue and SGLT2 inhibitor ± metformin * 60 patients treated with GLP-1 agonist as a second step after metformin * 60 patients treated with SGLT2 inhibitor as a second step after metformin * 60 patients treated with a combination of insulin and other antidiabetic agents (metformin - DPP4 inhibitors) Individuals will be equal distributed as far as age, gender and body mass index concerned. In addition, patients suffered from kidney disease and retinopathy are excluded.
Official title: The Effect of GLP-1 Agonist, SGLT2 Inhibitor and Their Combination on Endothelial Function, Arterial Stiffness and Left Ventricular Deformation in Patients With Type 2 Diabetes With High Cardiovascular Risk
Key Details
Gender
All
Age Range
45 Years - 80 Years
Study Type
OBSERVATIONAL
Enrollment
240
Start Date
2017-11-03
Completion Date
2027-06-30
Last Updated
2026-03-13
Healthy Volunteers
No
Conditions
Locations (1)
"Attikon" University General Hospital
Athens, Attica, Greece